Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Pediatr Health Care ; 33(3): e1-e8, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30630642

RESUMO

INTRODUCTION: Researchers evaluated the prescribing of medications that induce somnolence to children with attention deficit hyperactivity disorder (ADHD) insured by Medicaid. METHOD: An observational study of prescription claims for children ages 3-18 with ADHD-associated ICD 9 diagnoses filled between January 1, 2012 and December 31, 2016 in Oregon. RESULTS: There were 14,567 prescriptions written for a 30-day supply of sleep medication for 2,518 children. Most were written for males (66.3%) and to those ages 12-18 (63.8%). Trazodone, hydroxyzine, quetiapine, clonazepam, and amitriptyline were frequently prescribed. There were few prescriptions for zaleplon and zolpidem. DISCUSSION: Trazodone, hydroxyzine, and amitriptyline are commonly prescribed without clinical efficacy or guidance for children with ADHD. Quetiapine is prescribed off label in sub-therapeutic doses for its somnolence effect. Mental health drugs, which have voluntary formulary guidance in Oregon, and antihistamines on formulary, are more frequently prescribed for children with ADHD than drugs with FDA approval for insomnia.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Hipnóticos e Sedativos/uso terapêutico , Medicaid , Padrões de Prática Médica/estatística & dados numéricos , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Adolescente , Transtorno do Deficit de Atenção com Hiperatividade/complicações , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Transtorno do Deficit de Atenção com Hiperatividade/fisiopatologia , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Estudos Retrospectivos , Distúrbios do Início e da Manutenção do Sono/epidemiologia , Distúrbios do Início e da Manutenção do Sono/etiologia , Distúrbios do Início e da Manutenção do Sono/fisiopatologia , Estados Unidos/epidemiologia , United States Food and Drug Administration
2.
J Pediatr Pharmacol Ther ; 22(6): 423-429, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29290742

RESUMO

OBJECTIVE: This study examines off-label medication prescribing use and trends in children on Medicaid with ADHD with particular focus on the very young (under age 6 years). METHODS: This was an observational cohort study and retrospective analysis of ADHD medication prescriptions from Oregon Medicaid records (N = 83,190) in 2012. Manufacturer prescribing information was used to determine off-label designation. Children ages 3 to 18 years at the time of prescription who had continuous Medicaid enrollment of at least 10 months during the index year of 2012 were included in the sample frame. RESULTS: Children with ADHD were prescribed off-label medications primarily at the ages of 5 years and younger. Among children ages 3 to 5 years, 91.4% of prescriptions were off-label. After the age of 5 years, the percentage of off-label prescriptions dropped notably to 21%, reflecting the increase in availability of approved medications for the treatment of ADHD starting at age 6 years. In the 3- to 5-year-old age group, specific off-label and concerning medication-related observations included a high frequency of alpha agonist (e.g., guanfacine, clonidine) prescribing; the prescribing of untested formulations such as clonidine patches; prescribing of atomoxetine; and prescribing of large doses of stimulant medications. CONCLUSIONS: Most ADHD drugs prescribed for very young children are off-label, which is concerning owing to lack of safety and efficacy data in this vulnerable population.

3.
J Child Adolesc Psychopharmacol ; 26(6): 548-54, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27135134

RESUMO

OBJECTIVE: This study compares nurse practitioner (NP) and physician (MD/DO) prescribing patterns for treatment of children with an attention-deficit/hyperactivity disorder (ADHD)-related diagnosis covered by Oregon Medicaid from 2012 to 2013. METHODS: This study is a limited data set review of Oregon pharmacy claims for youth aged 3-18 at time of prescription fill, who were continuously enrolled for at least 10 months of the index year. Claims with selected ICD-9 codes (n = 197,364) were further defined by 30-day prescriptions and prescription drug events (PDE) linked to each prescriber type of interest. Descriptive statistical analysis of variables included prescriber type (NP vs. physician) and specialty (generalist vs. specialist), child age, and controlled versus noncontrolled drug type. RESULTS: A total of 82,754 complete 30-day prescriptions for 10,753 children from 1785 unique prescribers (78 NP specialists; 303 NP generalists; 162 physician specialists; and 1242 physician generalist prescribers) and 16,669 PDE were analyzed. Physicians prescribed more than 81% of all ADHD medications, and physician generalists prescribed nearly 60% of all prescriptions. Sixty-four percent of 30-day supply prescriptions (n = 52,678) were controlled substances. Generalists, both NPs and physician prescribers, prescribed controlled medications more often than specialists. Physician specialists consistently prescribed controlled substances for all age groups, while NP specialists prescribed more controlled substances as child age increased. Rates of controlled medications prescribed generally increased, as children got older, regardless of provider type. CONCLUSION: NPs overall prescribe in a similar pattern to physicians when given the authority to prescribe controlled substances for ADHD. Comparisons between prescriber types for controlled substance prescribing by age should be explored further to identify possible variance from national guidelines.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Padrões de Prática em Enfermagem/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Medicamentos sob Prescrição/administração & dosagem , Adolescente , Fatores Etários , Criança , Pré-Escolar , Substâncias Controladas/administração & dosagem , Feminino , Humanos , Classificação Internacional de Doenças , Masculino , Medicaid , Oregon , Especialização/estatística & dados numéricos , Estados Unidos
4.
JAMA ; 315(17): 1864-73, 2016 May 03.
Artigo em Inglês | MEDLINE | ID: mdl-27139059

RESUMO

IMPORTANCE: The National Action Plan for Combating Antibiotic-Resistant Bacteria set a goal of reducing inappropriate outpatient antibiotic use by 50% by 2020, but the extent of inappropriate outpatient antibiotic use is unknown. OBJECTIVE: To estimate the rates of outpatient oral antibiotic prescribing by age and diagnosis, and the estimated portions of antibiotic use that may be inappropriate in adults and children in the United States. DESIGN, SETTING, AND PARTICIPANTS: Using the 2010-2011 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, annual numbers and population-adjusted rates with 95% confidence intervals of ambulatory visits with oral antibiotic prescriptions by age, region, and diagnosis in the United States were estimated. EXPOSURES: Ambulatory care visits. MAIN OUTCOMES AND MEASURES: Based on national guidelines and regional variation in prescribing, diagnosis-specific prevalence and rates of total and appropriate antibiotic prescriptions were determined. These rates were combined to calculate an estimate of the appropriate annual rate of antibiotic prescriptions per 1000 population. RESULTS: Of the 184,032 sampled visits, 12.6% of visits (95% CI, 12.0%-13.3%) resulted in antibiotic prescriptions. Sinusitis was the single diagnosis associated with the most antibiotic prescriptions per 1000 population (56 antibiotic prescriptions [95% CI, 48-64]), followed by suppurative otitis media (47 antibiotic prescriptions [95% CI, 41-54]), and pharyngitis (43 antibiotic prescriptions [95% CI, 38-49]). Collectively, acute respiratory conditions per 1000 population led to 221 antibiotic prescriptions (95% CI, 198-245) annually, but only 111 antibiotic prescriptions were estimated to be appropriate for these conditions. Per 1000 population, among all conditions and ages combined in 2010-2011, an estimated 506 antibiotic prescriptions (95% CI, 458-554) were written annually, and, of these, 353 antibiotic prescriptions were estimated to be appropriate antibiotic prescriptions. CONCLUSIONS AND RELEVANCE: In the United States in 2010-2011, there was an estimated annual antibiotic prescription rate per 1000 population of 506, but only an estimated 353 antibiotic prescriptions were likely appropriate, supporting the need for establishing a goal for outpatient antibiotic stewardship.


Assuntos
Assistência Ambulatorial/estatística & dados numéricos , Antibacterianos/uso terapêutico , Prescrição Inadequada/estatística & dados numéricos , Otite Média Supurativa/tratamento farmacológico , Padrões de Prática Médica/estatística & dados numéricos , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Pesquisas sobre Atenção à Saúde , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Faringite/tratamento farmacológico , Prevalência , Infecções Respiratórias/tratamento farmacológico , Estados Unidos
5.
J Pediatr Health Care ; 30(2): 173-82; quiz 183-4, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26896379

RESUMO

Because some parents are choosing to not vaccinate or only partially vaccinate their children, vaccine-preventable diseases that once were rarely seen in pediatric practice must now be considered part of the differential diagnosis when caring for these children. Measles, mumps, varicella, meningococcal disease, pertussis, and influenza are reviewed. Recommendations for prevention and treatment of these vaccine-preventable diseases are discussed.


Assuntos
Varicela/terapia , Influenza Humana/terapia , Sarampo/terapia , Caxumba/terapia , Profilaxia Pós-Exposição/métodos , Rubéola (Sarampo Alemão)/terapia , Vacinas/imunologia , Coqueluche/terapia , Varicela/epidemiologia , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Influenza Humana/epidemiologia , Sarampo/epidemiologia , Caxumba/epidemiologia , Rubéola (Sarampo Alemão)/epidemiologia , Vigilância de Evento Sentinela , Estados Unidos/epidemiologia , Vacinação/estatística & dados numéricos , Coqueluche/epidemiologia
6.
J Pediatr Health Care ; 27(2): 135-44, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23414979

RESUMO

Adolescents have access to a variety of legal or illicit substances that they use to alter their mood or "get high." The purpose of this review is to provide an overview of common substances adolescents use to get high, including the illicit substances synthetic marijuana or "Spice," salvia, MDMA, synthetic cathinones, and 2C-E. Dextromethorphan and energy drinks are easily accessible substances that teenagers abuse. The toxic effects of common ingestions and treatment of overdose is discussed to inform pediatric providers who provide care for adolescents.


Assuntos
Comportamento do Adolescente , Benzodioxóis/toxicidade , Agonistas de Receptores de Canabinoides/toxicidade , Canabinoides/toxicidade , Dextrometorfano/toxicidade , N-Metil-3,4-Metilenodioxianfetamina/toxicidade , Pirrolidinas/toxicidade , Transtornos Relacionados ao Uso de Substâncias/prevenção & controle , Adolescente , Comportamento do Adolescente/psicologia , Benzodioxóis/efeitos adversos , Agonistas de Receptores de Canabinoides/efeitos adversos , Canabinoides/efeitos adversos , Carvão Vegetal/uso terapêutico , Dextrometorfano/efeitos adversos , Overdose de Drogas , Medicina de Emergência/métodos , Feminino , Humanos , Drogas Ilícitas , Masculino , N-Metil-3,4-Metilenodioxianfetamina/efeitos adversos , Naloxona/uso terapêutico , North Carolina/epidemiologia , Ondansetron/uso terapêutico , Prevalência , Pirrolidinas/efeitos adversos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Catinona Sintética
7.
J Pediatr Health Care ; 24(4): 258-66; quiz 267-9, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20620852

RESUMO

The 2009 H1N1 influenza pandemic took health care workers worldwide by surprise. Early in the course of the pandemic it was determined that children and pregnant women were at high risk of increased morbidity and mortality from the novel influenza virus. The Centers for Disease Control and Prevention and state and local public health officials quickly rallied to develop treatment guidelines for the new strain of influenza A, including emergency approvals for off-label use of some antiviral drugs. Prevention of the spread of influenza via vaccination and environmental controls is critical to the health of children. The 2009 H1N1 influenza virus emerged too late to be included in the 2009/2010 seasonal influenza vaccine, so production of a monovalent vaccine was set in motion. Five months from when the first cases of novel H1N1 appeared in Mexico and the United States, a vaccine was being distributed to high-risk patients. Looking ahead to the 2010/2011 influenza season, it is difficult to predict 2009 H1N1 activity. The 2010/2011 seasonal influenza vaccine will include the 2009 H1N1 strain, so it is critical to get all children vaccinated early in the flu season.


Assuntos
Vírus da Influenza A Subtipo H1N1/isolamento & purificação , Influenza Humana/epidemiologia , Antivirais/uso terapêutico , Educação Continuada , Humanos , Influenza Humana/tratamento farmacológico , Influenza Humana/transmissão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...